← Back to Analyst Consensus 
DAWN Hold
Day One Biopharmaceuticals, Inc.
Current Price —
Implied Upside —
Analysts 13
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Oct 28, 2026 (2 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Mar 11, 2026 | JP Morgan | downgrade | Overweight → Neutral | — | 54% |
| Mar 10, 2026 | HC Wainwright & Co. | downgrade | Buy → Neutral | — | 44% |
| Mar 9, 2026 | Wedbush | downgrade | Outperform → Neutral | — | 58% |
| Mar 6, 2026 | Jones Trading | downgrade | Buy → Hold | — | 50% |
| Mar 6, 2026 | Needham | downgrade | Buy → Hold | — | 50% |
| Feb 25, 2026 | Wedbush | maintain | Outperform → Outperform | $30 | 58% |
| Feb 25, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $22 | 44% |
| Feb 25, 2026 | Needham | maintain | Buy → Buy | $17 | 50% |
| Jan 13, 2026 | TD Cowen | initiate | — → Buy | $34 | 54% |
| Nov 24, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| Nov 24, 2025 | Needham | reiterate | Buy → Buy | $16 | 50% |
| Nov 7, 2025 | JP Morgan | maintain | Overweight → Overweight | $27 | 54% |
| Nov 5, 2025 | Piper Sandler | maintain | Overweight → Overweight | $26 | 54% |
| Aug 6, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $25 | 44% |
| Aug 6, 2025 | Needham | maintain | Buy → Buy | $16 | 50% |
| May 7, 2025 | Needham | maintain | Buy → Buy | $27 | 50% |
| Apr 3, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $36 | 44% |
| Mar 25, 2025 | Goldman Sachs | maintain | Buy → Buy | $27 | 54% |
| Mar 5, 2025 | JP Morgan | maintain | Overweight → Overweight | $34 | 54% |
| Feb 26, 2025 | Wedbush | reiterate | Outperform → Outperform | $32 | 58% |
| Feb 26, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $36 | 44% |
| Feb 26, 2025 | Needham | reiterate | Buy → Buy | $32 | 50% |
| Feb 10, 2025 | Goldman Sachs | maintain | Buy → Buy | $43 | 54% |
| Jan 13, 2025 | Needham | reiterate | Buy → Buy | $33 | 50% |
| Jan 7, 2025 | B of A Securities | maintain | Buy → Buy | $25 | 53% |
| Dec 17, 2024 | Jones Trading | maintain | Buy → Buy | $34 | 50% |
| Oct 31, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $40 | 44% |
| Oct 31, 2024 | Needham | reiterate | Buy → Buy | $33 | 50% |
| Oct 9, 2024 | Needham | maintain | Buy → Buy | $33 | 50% |
| Aug 6, 2024 | JP Morgan | maintain | Overweight → Overweight | $36 | 54% |
| Aug 1, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $40 | 44% |
| Aug 1, 2024 | B of A Securities | upgrade | Underperform → Buy | $24 | 53% |
| Jul 31, 2024 | Needham | maintain | Buy → Buy | $32 | 50% |
| Jul 30, 2024 | Needham | reiterate | Buy → Buy | $33 | 50% |
| Jul 26, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $40 | 44% |
| Jul 8, 2024 | Piper Sandler | maintain | Overweight → Overweight | $40 | 54% |
| Jun 20, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $40 | 44% |
| Jun 19, 2024 | Needham | reiterate | Buy → Buy | $33 | 50% |
| May 7, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $40 | 44% |
| May 7, 2024 | Needham | reiterate | Buy → Buy | $33 | 50% |
| Apr 25, 2024 | Needham | reiterate | Buy → Buy | $33 | 50% |
| Apr 24, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $50 | 44% |
| Apr 24, 2024 | Needham | maintain | Buy → Buy | $33 | 50% |
| Apr 22, 2024 | JP Morgan | maintain | Overweight → Overweight | $36 | 54% |
| Mar 26, 2024 | Piper Sandler | maintain | Overweight → Overweight | $40 | 54% |
| Feb 28, 2024 | Piper Sandler | maintain | Overweight → Overweight | $40 | 54% |
| Feb 27, 2024 | Goldman Sachs | maintain | Buy → Buy | $44 | 54% |
| Feb 27, 2024 | Oppenheimer | reiterate | Perform → Perform | $0 | 52% |
| Nov 7, 2023 | Wedbush | maintain | Outperform → Outperform | $35 | 58% |
| Nov 7, 2023 | Needham | reiterate | Buy → Buy | $34 | 50% |
Price Target Trend
Apr 17, 2026 Latest: $21.5 Jun 19, 2026
EPS Estimates
0q $-0.17
Lo: $-0.28 Hi: $-0.09
6 analysts +1q $-0.16
Lo: $-0.28 Hi: $-0.03
6 analysts +1y $-0.04
Lo: $-0.46 Hi: $0.35
6 analysts 0y $-0.76
Lo: $-1.76 Hi: $-0.16
7 analysts Cross-Platform Signals
No cross-platform signals in the last 90 days